According to Markntel Advisors Report, Liquid Biopsy Market is expected to grow at a significant growth rate, and the analysis period is 2023-2028, considering the base year as 2022.Consistent monitoring and evaluating of market dynamics to stay informed and adapt your strategies accordingly. As a market research and consulting firm, we offer market research reports that focus on major parameters including Target Market Identification, Customer Needs and Preferences, Thorough Competitor Analysis, Market Size & Market Analysis, and other major factors. At the end, we do provide meaningful insights and actionable recommendations that inform decision-making and strategy development.

Liquid Biopsy is a laboratory test done on a sample of blood, urine, or other body fluids to look for remnants of cancer cells, from tumor to slightest strain, like DNA, RNA, or other molecules released by tumorous cancer cells into the body’s fluids. It can be applied to screen early cancer, track cancer/tumor progression, assess clinical prognosis, detect recurrent tumor cells, and more. It has gained attention and is appreciated as a non-invasive technique as it is less bodily taxing than tissue biopsy due to technological advances.

 

Global Liquid Biopsy Market Research Report & Summary:

The Global Liquid Biopsy Market is projected to grow at a CAGR of around 26% during the forecast period, i.e., 2023-28.                      

Time Period Captured in the Report:

• Historical Years: 2018-21
• Base Years: 2022
• Forecast Years: 2023-28

Who are the Key Players Operating in the Liquid Biopsy Market?

The top companies of the Liquid Biopsy Market ruling the industry are: 

Bio-Rad Laboratories, Biocept Inc, Abcodia Ltd, Chronix Biomedical, Epic Sciences Inc, Hoffmann-La Roche AG, Cynvenio Biosystems, Inc., GUARDANT HEALTH, INC, Illumina, Inc., NeoGenomics Laboratories, Inc., Menarini Silicon Biosystems, Inc., Qiagen N.V., Thermo Fisher Scientific, Personal Genome Diagnostics, Inc., Qiagen N.V. etc.

✅In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report. 

Access the detailed PDF Sample report – https://www.marknteladvisors.com/query/request-sample/global-liquid-biopsy-market.html

(“Kindly use your official email ID for all correspondence to ensure seamless engagement and access to exclusive benefits, along with prioritized support from our sales team.”)

What is Included in Liquid Biopsy Market Segmentation?

The Liquid Biopsy Market explores the industry by emphasizing the growth parameters and categorizes including geographical segmentation, to offer a comprehensive understanding of the market dynamic.  The further bifurcations are as follows:

• By Work Process
  • Sample Preparation               
  • Library Preparation
  • Sequencing
  • Data Analysis         
• By Technology
  • PCR
    • RT-PCR
    • dPCR
    • Multiplex PCR
    • Others
  • NGS
  • FISH
  • Other Technologies
• By Usage
  • RUO
  • Clinical
• By Sample Type
  • Blood
  • Urine
  • Saliva
  • Cerebrospinal Fluid
• By Products
  • Test /Services
  • Kits and Consumables
  • Instruments
• By Circulating Biomarkers
  • Circulating Tumor Cells
  • Cell-free DNA
  • Circulating Cell-Free RNA   
  • Exosomes and Extracellular Vesicles           
  • Others                     
• By Disease Type
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma
  • Other Cancers
  • Non-Oncology Disorders
• By Clinical Application
  • Treatment Monitoring
  • Prognosis and Recurrence Monitoring
  • Treatment Selection
  • Diagnosis and Screening
• By Region
  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

 

Explore the Complete Liquid Biopsy Market Analysis Report – https://www.marknteladvisors.com/research-library/global-liquid-biopsy-market.html

Global Liquid Biopsy Market Dynamics:

Key Driver: Surge in Cancer Cases Across the Globe

The number of cancer cases has surged significantly on a global scale. Environmental factors are the leading causes of cancer. The rise in cancer diagnosis has led various countries and international health organizations to undertake various initiatives to spread awareness about cancer. With this increase, Liquid biopsy is preferred for its multiple advantages, counting low-cost, early prognosis, tumor heterogeneity identification, drug resistance, therapeutic drug monitoring, and the most ascendant, patient comfort by eliminating the need for surgery. Consecutively, this increase in preference for Liquid Biopsies is expected to increase the Market during the forecasting period.

Possible Restraint: Compatibility of Liquid Biopsies with Specific Kinds and Stages of Cancer

Detecting ctDNA through Liquid Biopsy becomes technically tricky as the quantities of ctDNA may be lower in the plasma of a cancer patient for particular cancer mutations, especially after the treatment and surgery. It is also not applicable to all cancers, as certain tumors do not shed a recognizable amount of ctDNA. Also, there may be fewer than one detectable copy of the cancer mutation containing ctDNA in a patient’s sample, resulting in ctDNA not being identified, even though ctDNA is deficient. As a result, the credibility is lessened, as it might give a false negative where ctDNA is not identifiable. This discrepancy could negatively hinder the market.

Need personalized insights? Click here to customize this report- https://www.marknteladvisors.com/query/request-customization/global-liquid-biopsy-market.html

Why Markntel Advisor Report?

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.

For Further Queries:

Contact Us

MarkNtel Advisors

Email at –sales@marknteladvisors.com

Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh – 201281, India